Dr Meri Muminovic speaks to ecancer at the Best of ASCO®️ 2024 Miami Symposium about highlights from the meeting’s lung cancer session.

She explains that the studies included treatment using EGFR inhibitors, MAT inhibitors and antibody drug conjugates (ADCs).

Dr Muminovic believes that there have been important advancements this year in the management of EGFR and ALK inhibitors used for the treatment of lung cancer.